Top 20 Oncology Companies of 2025

Shots: ADCs, cell therapies, and radioligand therapies are reshaping oncology, while biopharma companies focus on smarter trials, patient-first approaches, and faster access to bridge unmet needs in cancer care In 2024, the global oncology market was valued at $225.01B and is projected to reach $668.26B by 2034, reflecting a strong CAGR of 11.5% from 2025…

ByPrince GiriSeptember 3, 2025

TOP 20

Top 20 Oncology Companies of 2024

Shots: With more than 50 percent of ongoing clinical trials, Oncology remains one of the most explored therapy areas in healthcare In 2023, the global oncology market was valued at $222.36B and is envisioned to grow to $521.6B by 2033, registering a CAGR of 8.9% from 2024 to 2033. With $27.6B registered oncology revenue, Merck…

ByPrince GiriAugust 29, 2024

TOP 20

Top 20 Immunology Companies of 2024

Shots: Immunology remains one of the most explored therapy areas. Companies focusing on immunology are steadfastly working to advance treatment options by developing drugs, vaccines, and antibodies In 2023, the global immunology market size was valued at $98.22B and expected to register $263.22B by 2033, with a CAGR of 10.36% from 2024 to 2033. AbbVie…

ByPrince GiriJuly 25, 2024

INSIGHTS+

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020. Date…

BySenior EditorFebruary 7, 2020

TOP 20

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a list of…

ByPrince GiriJanuary 3, 2020

TOP 20

Top 20 Life Sciences Deals of 2018 Based on Total Deal Value

Healthcare- pharmaceutical- and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in 2018. The highest valued deal proved to be of Takeda's acquisition of Shire for $57B with the focus on global R&D- its robust and modality-diverse…

ByPrince GiriAugust 23, 2019

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2019

The first quarter of 2019 has marked with major events in the pharma & biotech industries. We have gathered the key highlights of the quarter, which was starting with the blockbuster news, where Celgene had acquired BMS for $74B. Moving to the next news, acquisition of Loxo Oncology for $8B, in addition to Spark Therapeutics…

BySenior EditorAugust 4, 2019

TOP 20

Top 10 Oncology Companies By 2018 Revenue

The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced- effective- and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top…

ByPrince GiriMay 31, 2019

TOP 20

Top 20 BioPharma Companies based on 2018 Total Revenue

The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics & devices- which were emerged as one of major revenue generator in 2018- with the development of new products and devices. The year 2018 also proved to be a record with approval of 55…

ByPrince GiriMay 1, 2019

Top 20 Oncology Companies of 2025

Top 20 Oncology Companies of 2024

Top 20 Immunology Companies of 2024

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

Top 20 Life Sciences Deals of 2018 Based on Total Deal Value

PharmaShots’ Key Highlights of First Quarter 2019

Top 10 Oncology Companies By 2018 Revenue

Top 20 BioPharma Companies based on 2018 Total Revenue

Contact US

OUR INFORMATION

FOLLOW US